Upfront Briefing
A heavy data tape: Cytokinetics' aficamten cleared the high bar in non-obstructive HCM, doubling the addressable franchise. Avalo paired clean Phase 2 HS data with a $375M raise, and Viridian delivered a second positive Phase 3 in chronic TED.
On the earnings/strategy side, Novo Nordisk raised 2026 guidance on the back of a record-pace Wegovy pill launch (2M+ scripts since January), Pfizer beat Q1 but held the line on FY26, and BioNTech detailed plans to close 4 manufacturing sites and cut 1,860 jobs as it pivots harder into oncology.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 | 7,259.2 | +0.8% | +5.5% |
| Nasdaq 100 | 28,015.1 | +1.3% | +12.5% |
| Russell 2000 | 2,845.0 | +1.8% | +8.4% |
| Healthcare (XLV) | 145.3 | +0.4% | (6.5%) |
| Biotech (XBI) | 133.8 | +0.2% | +6.8% |
| Nasdaq Biotech (NBI) | 5,910.2 | +0.2% | (0.3%) |
| Clinical Trials (BBC) | 44.9 | (0.0%) | +9.6% |
|
- Risk-on returned (Russell 2000 +1.8% to a fresh intraday record, Nasdaq 100 +1.3%) as oil rolled over (WTI -3.9% to $102.27) on a holding US-Iran ceasefire, taking pressure off duration and small caps.
- Tech led the broader bid, with Micron +10% through a $700B market cap on an HBM-sold-out-through-2026 narrative; Pfizer's Q1 beat ($14.5B revenue, +2% Y/Y) added defensive support.
- Healthcare lagged (XLV +0.4%) and biotech only modestly green (XBI +0.2%, NBI +0.2%), confirming this was a generalist risk-on day rather than a dedicated biotech bid — despite a heavy single-name catalyst tape (Cytokinetics, Viridian, Avalo).
- Clinical-trials beta (BBC) flat on the day, underscoring that early-stage biotech still isn't getting paid for the macro tailwind.
- Market data: U.S. close Tue 05-May-2026.
The Big 3
|
1
|
Cytokinetics' aficamten clears ACACIA-HCM in non-obstructive HCM
|
- ACACIA-HCM hit both dual primary endpoints at Week 36 vs placebo: KCCQ-CSS LSM diff +3.0 (p=0.021) and pVO2 +0.67 mL/kg/min (p=0.003), with consistent benefit across key secondaries. LVEF <50% occurred in 10% of aficamten patients vs 1% on placebo, a watch item but in line with the class. Cytokinetics plans FDA discussions and an upcoming medical meeting presentation.
- Why it matters: nHCM roughly doubles the addressable HCM population and is currently a label-free market — a clean read here is the cleanest possible setup for a sNDA and a step-up in the consensus peak sales build for aficamten/MYQORZO. Investors will now focus on the LVEF safety profile vs Camzyos, payer coverage in a non-obstructive label, and read-through to Edgewise (EWTX) and BMY's Camzyos franchise. The pVO2 hit is the harder bar in a heterogeneous population, which makes this readout particularly de-risking.
- Source: PR
|
|
2
|
Avalo: clean Phase 2 HS data + $375M raise back-to-back
|
- Phase 2 LOTUS (n=253) hit HiSCR75 at Week 16 with response rates of 42.2% (150 mg, p=0.018) and 42.9% (300 mg, p=0.015) vs 25.6% on placebo — Avalo flags these as the highest HiSCR75 rates in any HS trial of this size. Statistically significant benefit on HiSCR50, IHS4 and draining tunnel count; abdakibart was well tolerated. Avalo concurrently priced a $375M offering at $17.75/share to fund the registrational Phase 3.
- Why it matters: HS remains a high-need inflammatory market validated by Humira/Cosentyx but with a wide-open opportunity for higher-bar responders. A 17pp placebo-adjusted HiSCR75 delta is a credible competitive profile, and the offering removes the financing overhang that typically caps post-data trades. The investor focus shifts to Phase 3 dose selection, durability beyond Week 16, and how abdakibart positions against UCB's bimekizumab and Novartis' sonelokimab in the next-gen HS race.
- Source: Data PR; Offering PR
|
|
3
|
Viridian: REVEAL-2 makes elegrobart a two-trial chronic TED story
|
- REVEAL-2 (n=204) met its primary endpoint, with proptosis responder rates of 50% (Q4W) and 54% (Q8W) vs 15% placebo at Week 24, plus a statistically significant diplopia responder benefit on Q4W. Elegrobart is a subcutaneous, half-life-extended IGF-1R mAb — same target class as Tepezza but designed for an at-home autoinjector. Shares jumped ~25% pre-market.
- Why it matters: The investor debate in TED is no longer about IGF-1R efficacy — it's about route of administration, durability and access. A second positive Phase 3 (after REVEAL-1) with IV-like proptosis response on a Q8W subcut autoinjector is the differentiation Viridian needs to defend a premium share-of-voice fight against Amgen/Horizon's Tepezza and the active-TED launch of veligrotug. The setup tightens the BLA narrative and reframes elegrobart as a serious chronic-TED franchise — not a single-readout trade.
- Source: PR
|
Everything Else that broke
- Novo Nordisk raises FY26 guidance to a 4–12% adj. sales/op profit decline (vs prior 5–13%) on Wegovy pill momentum (2M+ scripts since January launch). — PR
- BioNTech to close 4 manufacturing sites (Marburg, Idar-Oberstein, Tübingen, Singapore) and cut up to 1,860 jobs; targeting up to €500M annual savings by 2029 to fund oncology pipeline. — Fierce Pharma
- Pfizer Q1: $14.5B revenue (+2% Y/Y, +7% ex-COVID), beats consensus; FY26 guide reiterated at $59.5–62.5B. Vyndamax LOE pushed to 2031 underpins the "2029 inflection" pitch. — BioSpace
- QurAlis: interim Phase 1/2 ANQUR data show QRL-201 (STMN2-targeting ASO) slowed sporadic ALS progression by up to 50% in 69 patients, with CSF NfL/pNfH reductions; Phase 3 prep underway for 2027. — BioSpace
- Relay Therapeutics: FDA Breakthrough Therapy designation for zovegalisib in PIK3CA-mutant HR+/HER2- advanced breast cancer; selected zovegalisib + atirmociclib triplet for 1L Phase 3 (early 2027 start). — PR
- IDEAYA initiates rolling NDA submission for darovasertib (OptimUM-02) under FDA's Real-time Oncology Review program. — Stock Titan
- J&J's Ottava soft-tissue surgical robot hits primary endpoints in pivotal study. — J&J
- BioCentury flags at least five PDUFA dates on FDA's May docket. — BioCentury
- Alebund completes Phase 3 enrollment for AP301 in hyperphosphatemia. — PR
- Q1 prints: Adaptive Biotechnologies, Myriad Genetics (FY26 guide reiterated), Trevi Therapeutics, Dianthus, Theriva. — Myriad · Adaptive · Trevi · Dianthus · Theriva
- ARVO presentations: MingMed positive Phase 2 QA102 in intermediate AMD; Neuvasq preclinical BRB-restoration antibody data. — MingMed · Neuvasq
- Upcoming readouts/posters: Biomea Fusion icovamenib at ADA; Verrica VP-315 Phase 2 BCC at SID 2026. — Biomea · Verrica
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
INmune Bio, Anthony Nolan expand CORDStrom MSC collaboration. — PR
-
Madrigal licenses Arrowhead phase 1 MASH asset in up-to-$1B biobucks deal, including $25M upfront. — Fierce Biotech
VC / Private Financings
- Cytospire Therapeutics (UK) closes oversubscribed £61M ($83M) Series A to advance pan–gamma delta T cell engager CYT X300 (EGFR+ solid tumours) toward IND. Led by 4BIO Capital, with new investors Servier Ventures (notably the first-ever investment from Servier's newly-formed CVC), Sound Bioventures, British Business Bank and Criteria Bio Ventures, alongside existing investors Abingworth and LifeArc Ventures. — PR
IPOs / Follow-Ons
- Avalo Therapeutics prices $375M public offering. — PR
- Aura Biosciences closes $299M public offering, including full exercise of the underwriters’ option. — PR
- Ocugen prices $115M convertible senior notes due 2034. — PR
|
